Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder

Menopause

Volumn 18, Issue 9, 2011, Pages 962-966

  Nelken, Rebecca S ^a   Özel, Begüm Z ^a   Leegant, Ava R ^a   Felix, Juan C ^a   Mishell Jr , Daniel R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Estradiol vaginal ring; Overactive bladder; Oxybutynin; Vaginal estrogen

Indexed keywords

ESTRADIOL; OXYBUTYNIN;

ADULT; ARTICLE; BLURRED VISION; CONSTIPATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; NAUSEA; OVERACTIVE BLADDER; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VAGINA DISCHARGE; VAGINA RING; VOMITING; XEROSTOMIA;

AGED; CONTRACEPTIVE DEVICES, FEMALE; ESTRADIOL; FEMALE; HUMANS; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 80052422184     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3182104977     Document Type: Article

References (19)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardization subcommittee of the International Continence Society. Neurourol Urodyn 2002;21:167-178. (Pubitemid 34195211)
2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20: 327-336. (Pubitemid 44175300)
3. Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008;112:1311-1318.
4. Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG 2000;107:1029-1034. (Pubitemid 30495461)
5. Cardozo LD, Wise BG, Benness CJ. Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal womenV a double-blind placebo-controlled study. J Obstet Gynaecol 2001;21: 383-385. (Pubitemid 32735275)
6. Simuni V, Banovi I, Ciglar S, Jeren L, Pavici Baldani D, Sprem M. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 2003;82:187-197.
7. Zullo MA, Plotti F, Calcagno M, et al. Vaginal estrogen therapy and overactive bladder symptoms in postmenopausal patients after a tensionfree vaginal tape procedure: a randomized clinical trial. Menopause 2005;12:421-427. (Pubitemid 41098655)
8. Long CY, Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril 2006;85:155-160.
9. Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 1995;14:131-139.
10. Meisels A. The maturation value. Acta Cytol 1967;11:249-253.
11. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:283-289. (Pubitemid 29465392)
12. Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001;165:1452-1456. (Pubitemid 32410212)
13. Homma Y, Paick JS, Lee JG, Kawabe K, Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 2003;92:741-747. (Pubitemid 37475818)
14. Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A oneyear multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996;174:85-92. (Pubitemid 26037694)
15. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-92. (Pubitemid 40675125)
16. Casper F, Petri E. Local treatment of urogenital atrophy with an estradiolreleasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:171-176. (Pubitemid 29295094)
17. Gabrielsson J, Wallenbeck I, Birgerson L. Pharmacokinetic data on estradiol in light of the estring concept. Estradiol and estring pharmacokinetics. Acta Obstet Gynecol Scand Suppl 1996;163:26-31; discussion 32-34.
18. Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997;71:73-80. (Pubitemid 27045856)
19. Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 12A-estradiol in elderly women. Am J Obstet Gynecol 2002;186:944-947.